Related Experiment Video
Updated: Oct 29, 2025
14:59
Neuronavigation and Laparoscopy Guided Ventriculoperitoneal Shunt Insertion for the Treatment of Hydrocephalus
Published on: October 14, 2022
8.4K
PreserFlo MicroShunt® exposure: a case series
Roxane Bunod1, Mathieu Robin1, Juliette Buffault1,2
1Department of Ophthalmology III, Quinze-Vingts National Ophthalmology Hospital, 28 rue de Charenton, 75012, Paris, France.
BMC Ophthalmology
|July 11, 2021
Summary
PreserFlo MicroShunt (PM) exposure is a rare but serious complication for glaucoma patients. Pre-existing ocular surface inflammation and lack of a Tenon's flap increase the risk of this vision-threatening event.
Area of Science:
- Ophthalmology
- Glaucoma Surgery
- Medical Device Complications
Background:
- PreserFlo MicroShunt (PM) is a minimally invasive surgical device for open-angle glaucoma uncontrolled by medication.
- Adverse events associated with PM implantation are typically rare, mild, and transient.
Observation:
- Two cases of PreserFlo MicroShunt exposure are presented, occurring 7 days and 3 months post-implantation.
- Both cases involved patients with pre-existing blepharitis and lacked a Tenon's flap, necessitating device removal.
Findings:
- PreserFlo MicroShunt exposure is a potentially vision-threatening complication, carrying a risk of endophthalmitis.
- Absence of a Tenon's flap and pre-existing ocular surface inflammation are identified as potential risk factors.
Implications:
- Ocular surface inflammation should be treated before PM implantation.
- Close monitoring is crucial for patients with intraoperative Tenon's capsule deficiencies due to increased exposure risk.
